Epigenetic reprogramming induces the expansion of cord blood stem cells

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2378-2395

  Chaurasia, Pratima ^a   Gajzer, David C ^a   Schaniel, Christoph ^a   D'Souza, Sunita ^a   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ALDEHYDE DEHYDROGENASE; ALPHA6 INTEGRIN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; SMALL INTERFERING RNA; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CORD BLOOD STEM CELL TRANSPLANTATION; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL EXPANSION; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; ANTIGENS, CD34; ANTIGENS, THY-1; CULTURE MEDIA, SERUM-FREE; CYTOKINES; EPIGENESIS, GENETIC; FETAL BLOOD; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROGRAFTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, SCID; RNA, SMALL INTERFERING; VALPROIC ACID;

EID: 84902206817     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70313     Document Type: Article

References (63)

1. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood. 1997;90(12):4665-4678.
2. Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood. 2011;117(23):6083-6090.
3. Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biol Blood Marrow Transplant. 2013;19(1 suppl):S74-S78.
4. Navarrete C, Contreras M. Cord blood banking: a historical perspective. Br J Haematol. 2009;147(2):236-245.
5. Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev. 2009;23(5):199-204.
6. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115(9):1843-1849.
7. Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol. 2010;3(3):273-283.
8. Ballen KK, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13(1):82-89.
9. Rao M, Ahrlund-Richter L, Kaufman DS. Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells. 2012;30(1):55-60.
10. Giebel B, et al. Primitive human hematopoietic cells give rise to differentially specified daughter cells upon their initial cell division. Blood. 2006;107(5):2146-2152.
11. Ho AD, Wagner W. The beauty of asymmetry: asymmetric divisions and self-renewal in the haematopoietic system. Curr Opin Hematol. 2007;14(4):330-336.
12. Huang S, Law P, Francis K, Palsson BO, Ho AD. Symmetry of initial cell divisions among primitive hematopoietic progenitors is independent of ontogenic age and regulatory molecules. Blood. 1999;94(8):2595-2604.
13. -/lo cells in G0. Blood. 2005;105(8):3109-3116.
14. Boitano AE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345-1348.
15. De Felice L, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005;65(4):1505-1513.
16. Himburg HA, et al. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med. 2010;16(4):475-482.
17. Milhem M, et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood. 2004;103(11):4102-4110.
18. Nishino T, et al. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL. Exp Hematol. 2009;37(11):1364-1377.
19. North TE, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447(7147):1007-1011.
20. de Lima M, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008;41(9):771-778.
21. de Lima M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367(24):2305-2315.
22. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232-236.
23. Goessling W, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell. 2011;8(4):445-458.
24. Hoggatt J, et al. Differential stem- and progenitorcell trafficking by prostaglandin E2. Nature. 2013;495(7441):365-369.
25. O'Leary H, Ou X, Broxmeyer HE. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol. 2013;20(4):314-319.
26. Araki H, et al. Expansion of human umbilical cord blood SCID-repopulating cells using chromatinmodifying agents. Exp Hematol. 2006;34(2):140-149.
27. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood. 2007;109(8):3570-3578.
28. Azuara V, et al. Chromatin signatures of pluripotent cell lines. Nat Cell Biol. 2006;8(5):532-538.
29. Chaurasia P, Berenzon D, Hoffman R. Chromatinmodifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood. 2011;117(17):4632-4641.
30. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4(1):5.
31. Gul H, Marquez-Curtis LA, Jahroudi N, Lo J, Turner AR, Janowska-Wieczorek A. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev. 2009;18(6):831-838.
32. Asai T, et al. Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. Blood. 2012;120(8):1601-1612.
33. Li J. Quiescence regulators for hematopoietic stem cell. Exp Hematol. 2011;39(5):511-520.
34. Will B, et al. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nat Immunol. 2013;14(5):437-445.
35. Wilson A, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
36. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;333(6039):218-221.
37. Kramer OH, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003;22(13):3411-3420.
38. Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev Immunol. 2011;11(7):478-488.
39. Cunliffe VT. Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev. 2008;18(5):404-410.
40. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705.
41. Oh IH, Humphries RK. Concise review: multidimensional regulation of the hematopoietic stem cell state. Stem Cells. 2012;30(1):82-88.
42. Elizalde C, et al. Histone deacetylase 3 modulates the expansion of human hematopoietic stem cells. Stem Cells Dev. 2010;21(14):2581-2591.
43. Hess DA, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004;104(6):1648-1655.
44. Lioznov MV, Freiberger P, Kroger N, Zander AR, Fehse B. Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant. 2005;35(9):909-914.
45. Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood. 1995;85(4):1006-1016.
46. Storms RW, et al. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood. 2005;106(1):95-102.
47. Veeraputhiran M, Katragadda L, Balamurugan A, Cottler-Fox M. Aldehyde dehydrogenase as an alternative to enumeration of total and viable CD34 (+) cells in autologous hematopoietic progenitor cell transplantation. Cytotherapy. 2011;13(10):1256-1258.
48. Boyer LA, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122(6):947-956.
49. Loh YH, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38(4):431-440.
50. Redshaw Z, Strain AJ. Human haematopoietic stem cells express Oct4 pseudogenes and lack the ability to initiate Oct4 promoter-driven gene expression. J Negat Results Biomed. 2010;9(1):2-8.
51. Zangrossi S, et al. Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells. 2007;25(7):1675- 1680.
52. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.
53. Lim LS, et al. Zic3 is required for maintenance of pluripotency in embryonic stem cells. Mol Biol Cell. 2007;18(4):1348-1358.
54. Declercq J, Sheshadri P, Verfaillie CM, Kumar A. Zic3 enhances the generation of mouse induced pluripotent stem cells. Stem Cells Dev. 2013;22(14):2017-2025.
55. Sauvageau G, Iscove NN, Humphries RK. In vitro and in vivo expansion of hematopoietic stem cells. Oncogene. 2004;23(43):7223-7232.
56. Walasek MA, van Os R, de Haan G. Hematopoietic stem cell expansion: challenges and opportunities. Ann N Y Acad Sci. 2012;1266:138-150.
57. Hirai H, Katoku-Kikyo N, Karian P, Firpo M, Kikyo N. Efficient iPS cell production with the MyoD transactivation domain in serum-free culture. PLoS One. 2012;7(3):e34149.
58. Motabi IH, Di Persio JF. Advances in stem cell mobilization. Blood Rev. 2012;26(6):267-278.
59. Yu KR, et al. CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells. 2012;30(5):876-887.
60. Shivtiel S, et al. CD45 regulates homing and engraftment of immature normal and leukemic human cells in transplanted immunodeficient mice. Exp Hematol. 2011;39(12):1161-1170.
61. Colvin GA, Lambert JF, Dooner MS, Cerny J, Quesenberry PJ. Murine allogeneic in vivo stem cell homing (,). J Cell Physiol. 2007;211(2):386-391.
62. Aguila JR, et al. SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood. 2011;118(3):576-585.
63. O'Connor MD, Kardel MD, Eaves CJ. Functional assays for human embryonic stem cell pluripotency. Methods Mol Biol. 2011;690:67-80.